Literature DB >> 33024810

Anosognosia in dementia: A review of current assessment instruments.

Naomi S de Ruijter1, Anne M G Schoonbrood1, Björn van Twillert2, Erik I Hoff1.   

Abstract

INTRODUCTION: Anosognosia is a common but underrated symptom in dementia and has significant impact on both patients and caregivers. A proper evaluation of anosognosia is therefore desirable. There are three common methods to determine anosognosia: (1) clinical rating, (2) patient-caregiver discrepancies, and (3) prediction of performance discrepancies. Each of them includes different instruments. This review gives an overview of the current instruments used for the assessment of anosognosia in patients with dementia and aims to determine the most suitable instrument for routine use in clinical practice.
METHODS: A search of the literature in PubMed was performed. Furthermore, electronic databases (PsycINFo, ClinicalKey, and Cochrane Library) and reference lists were searched for additional articles.
RESULTS: Forty-six articles were included in this study, comprising 10 clinical rating instruments, 25 patient-caregiver discrepancy instruments, and 14 prediction-performance discrepancy instruments. For every publication, the aims of the study, the included population, the assessment instrument used, the assessed domains, and the psychometric properties of the assessment instruments are described.
CONCLUSIONS: Currently, there is no consensus on the most suitable method to determine anosognosia in dementia. We recommend the Clinical Insight Rating scale and the Abridged Anosognosia Questionnaire-Dementia as the most appropriate for routine use in clinical practice.
© 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Entities:  

Keywords:  Alzheimer's disease; anosognosia; assessment of anosognosia; dementia

Year:  2020        PMID: 33024810      PMCID: PMC7527687          DOI: 10.1002/dad2.12079

Source DB:  PubMed          Journal:  Alzheimers Dement (Amst)        ISSN: 2352-8729


INTRODUCTION

Anosognosia, a compound word derived from ancient Greek meaning “lack of knowledge of disease,” was first described by Joseph Babinski in 1914 (translation: Langer and Levine ). In the setting of dementia, the phenomenon of anosognosia can be defined as “unawareness of” or “impaired insight in” the patients’ deficits associated with dementia. Anosognosia may occur in multiple domains, such as the illness in general, specific cognitive deficits, affective changes, or activities of daily living. , There are three common assessment methods to determine anosognosia in people with dementia: Clinical rating: this is a quick method in which clinicians make an estimation of the patient's insight. , Disadvantages may be that the precise procedures vary regarding standardization of the questions (questionnaire, a semi‐structured interview, or observation ), that categories differ (eg, dichotomous, three‐point scale), and that the results are affected by factors relevant to the clinician (eg, experience). Furthermore, the patients’ responses may be guided by a desire to present themselves in the best possible way, which could be erroneously interpreted as denial of the problems and subsequently incorrectly termed as anosognosia. , , Patient‐caregiver discrepancies: this strategy is based on comparing the patient's self‐rating of performance on a functional domain with the caregiver's rating of the patient's performance on the same domain. , , Limitations are that it cannot differentiate between participants’ overestimation or informants’ underestimation. The outcome score may be influenced by participants’ ability to use the rating scale, and conversely, the caregiver may not be able to provide an accurate and objective rating. , Moreover, cut‐off scores are mostly arbitrary and validity of the instruments is rarely examined. Prediction of performance discrepancies: this strategy is based on the patient's self‐rating regarding the level of performance on a given task. The difference between the patient's own rating and the actual performance score is scored as the degree of anosognosia. , Disadvantages are that self‐ratings are affected by personal factors (such as mood or personality), are time‐consuming, and comprise the domain of memory performance only. , , Each of these methods has its own assessment instruments measuring different domains with their own psychometric properties. At this moment, there is no consensus on the most accurate assessment method or instrument. , , More recently, phenomenological and multidimensional methods for in‐depth assessment have been developed. These methods attempt to overcome limitations such as the dependence on questionnaire responses. Unlike many other measurement instruments, they take into account multiple domains in which deficits could occur in dementia. , Phenomenological and multidimensional methods are as yet barely represented in the literature. And because they require a considerable time investment, this limits their suitability for in‐depth assessment on the routine use in daily clinical practice. These methods will therefore not be further investigated in this review.

Key points

Anosognosia is a frequent phenomenon in dementia and has significant impact on both patients and especially caregivers. Since currently no consensus exists on the most suitable method, we reviewed available assessment instruments to determine anosognosia routinely in clinical practice. For this purpose, the Clinical Insight Rating Scale and the Abridged Anosognosia Questionnaire seem the most accurate diagnostic instruments.

RESEARCH IN CONTEXT

Systematic review: We performed a systematic search of the literature, primarily using PubMed. Original quantitative research, opinion papers, or reviews about anosognosia in dementia were included. Interpretation: Because of the significant impact of anosognosia on both patients with dementia and their caregivers, proper evaluation is warranted. Up until now, there is no consensus regarding the most accurate measurement instrument to determine anosognosia in daily clinical practice. In this report, we summarized the current methods for the assessment of anosognosia in dementia and provide recommendations for the most suitable options for routine use in clinical practice. Future directions: Although we propose the Clinical Insight Rating Scale and the Abridged Anosognosia Questionnaire—Dementia as the most suitable for clinical practice, there are still limitations to these measures. The absence of a gold standard precludes the validation of the various assessment instruments. Future research should focus on this. A uniform way to assess anosognosia is warranted for use in clinical practice. Patients with anosognosia present deficits in activities of daily living (ADL), or show changes in behavior such as disinhibition, irritability, and anxiety. Lack of uniform assessment can also hinder treatment as patients who are unaware of their deficits may exhibit reduced therapy compliance. Research shows that anosognosia significantly increases caregiver burden, for example by increasing physical symptoms or social isolation. A proper evaluation of anosognosia by health‐care professionals is therefore necessary. In turn, this should lead to person‐centered approaches, as understanding the existential world of the patient would make it easier to support patients and their families effectively. Up until now, there is no consensus regarding the most accurate measurement instrument to determine anosognosia. In this review, we aim to give an overview of the current instruments used for the assessment of anosognosia in dementia. The primary objective is to answer the following question: Which assessment instrument is the most suitable for use in daily clinical practice?

METHODS

A search of the literature was performed, using the PubMed database. The search strategy was developed with help of an information specialist. Relevant index terms and entry terms related to “Dementia,” “Alzheimer's disease,” “neuropsychological tests,” “assessment,” “scale,” “agnosia,” “awareness,” and “anosognosia” were selected. Other databases (PsycINFo, ClinicalKey, and Cochrane Library) and the references of relevant articles were searched for additional publications. The results were screened against the pre‐arranged eligibility criteria by one reviewer (NR). The inclusion criteria were: (1) original quantitative research, opinion papers, or reviews; (2) studies on participants with the diagnosis of dementia or probable dementia; (3) measurement tools on anosognosia as intervention; and (4) studies written in English. Exclusion criteria were: (1) other diseases not related to dementia and (2) other impairments not related to anosognosia. After selection of the eligible articles, data extraction was done by one reviewer (NR) and these data were checked by a second reviewer (AS). Any disagreement was resolved by discussion.

RESULTS

The PubMed search was conducted in August 2019 and yielded 859 citations. After screening, 46 articles were eligible for this study. For the selected articles, the three common strategies to determine anosognosia in people with dementia were elucidated: 10 clinical rating instruments, , , , , , , , , , 25 patient‐caregiver discrepancy instruments, , , , , , , , , , , , , , , , , , , , , , , , , and 14 prediction performance discrepancy instruments. , , , , , , , , , , , , , In Appendices I–III in supporting information, a summary of the eligible articles is presented. For every publication, the aims of the study, the included population, the assessment instrument used, the assessed domains, and the psychometric properties of the assessment instruments are described. In general, the study population consisted of patients with dementia. In most studies, the subjects were patients with probable or mild dementia (44 studies). Sample size varied from 12 to 670 patients. Concerning interpretation of the available psychometric data, the general cut‐off values were used. Appendix I presents 10 clinical rating instruments for the assessment of anosognosia. The procedures vary widely: conclusions may be based on a single question, , , , a regular clinical interview, a structured clinical interview, , , , or an observational tool. The rating system differs from a dichotomous outcome , to a nine‐point scale. Regarding domains of assessment, six instruments include multiple domains. , , , , , For these six instruments, psychometric properties were presented, which were all satisfactory. , , , , , Appendix II describes 25 patient‐caregiver discrepancy instruments. In all the studies, assessment of anosognosia depends on the calculation of discrepancy scores between patient and informant/caregiver. There are significant differences in the length of the assessment instruments (when mentioned), varying from 9 items to 108 items. In total, 15 instruments include multiple domains of assessment. , , , , , , , , , , , , , , Some psychometric properties were named for 10 instruments. , , , , , , , , , , , , The Anosognosia Questionnaire–Dementia has remarkable strong values (intrarater reliability 0.90 to 0.91, internal consistency 0.90 and 0.91). Appendix III gives an overview of the 14 prediction‐performance discrepancy instruments. Many of the presented instruments, eight in total, are based on self‐prediction performance on a memory test, compared to actual performance on this test. , , , , , , , In the other six instruments, multiple domains were assessed. , , , , , For only three instruments, psychometric properties were accurately described, all with good values. , ,

DISCUSSION

We aimed to describe the various strategies and instruments used to assess anosognosia in patients with dementia, and determine the most suitable screening instrument for routine clinical practice. Our search of the literature resulted in 46 eligible studies, comprising 49 different assessment instruments. When determining feasibility for general use in daily clinical practice, an assessment instrument should be quick and reliable. Currently, clinical ratings and patient‐caregiver discrepancies can be evaluated relatively rapidly. By contrast, prediction of performance discrepancies are more time consuming, covering the different domains more in‐depth. Therefore, we have chosen to look for the most suitable instruments only in the categories of clinical ratings and patient‐caregiver discrepancies. Furthermore, we have also placed emphasis on the included domains of assessment. Because anosognosia is a broad concept, good assessment should also involve multiple domains such as the patient's pattern of activities, emotions, behavior, and social factors. In the category of clinical rating instruments, only four assessment instruments assess multiple domains and also describe their psychometric properties. , , , One of these instruments was only used in patients with severe dementia and therefore not generally applicable for routine clinical practice. In our opinion, the Clinical Insight Rating Scale seems to be the most suitable option. This instrument is based on a systematic rating scale comprising four different domains, easily identified during a short clinical interview. It also has strong psychometric properties (interrater correlation 0.91, internal consistency 0.85). Of the described patient‐caregiver discrepancy instruments, we found seven assessment instruments with both multiple assessment domains and established psychometric properties. , , , , , , The instrument with the strongest psychometric properties is the Anosognosia Questionnaire—Dementia (AQ‐D; intrarater reliability 0.90 to 0.91, internal consistency 0.90 and 0.91). This instrument measures not only cognitive and functional performance, but also changes in behavior. However, it comprises 30 items and is therefore not suitable for rapid evaluation. We therefore propose the Abridged Anosognosia Questionnaire–Dementia (AAQ) as a suitable alternative for clinical practice. This questionnaire is an abbreviated version of the AQ‐D (nine items), still with strong psychometric properties (internal consistency 0.793, validity of the criteria compared to AQ‐D 0.800, and area under the receiver operating characteristic curve 0.946). Our review has some general limitations. Many of the included articles do not present specific data on validity (i.e. sensitivity and specificity) and psychometric properties (e.g. interrater reliability and internal consistency). This was already mentioned 15 years ago, in the review of Clare et al. which also showed that no uniform gold standard is available against which to measure assessment instruments. Furthermore, our review was not carried out to the standards of a full systematic search, because only one database was searched and only one reviewer selected articles for eligibility (although checked later by a second reviewer). Nevertheless, the presentt review gives a comprehensive overview of the current assessment tools for anosognosia and their psychometric properties, which has not been done in the last decade. In conclusion, anosognosia is a common phenomenon in patients with dementia and has significant impact on both patients and caregivers. Currently, no consensus for assessment in clinical practice exists. When comparing the current assessment instruments for anosognosia, we recommend the Clinical Insight Rating Scale and the Abridged Anosognosia Questionnaire–Dementia as the most appropriate for routine use in daily clinical practice.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest. Supplementary information Click here for additional data file.
  45 in total

1.  Relationship between denial of memory deficit and dementia severity in Alzheimer disease.

Authors:  S Sevush
Journal:  Neuropsychiatry Neuropsychol Behav Neurol       Date:  1999-04

Review 2.  Awareness in dementia: A review of assessment methods and measures.

Authors:  Linda Clare; Ivana Marková; Frans Verhey; Geraldine Kenny
Journal:  Aging Ment Health       Date:  2005-09       Impact factor: 3.658

3.  Awareness in dementia: conceptual issues.

Authors:  Ivana S Marková; Linda Clare; Michael Wang; Barbara Romero; Geraldine Kenny
Journal:  Aging Ment Health       Date:  2005-09       Impact factor: 3.658

4.  Anosognosia in Alzheimer's disease: the role of impairment levels in assessment of insight across domains.

Authors:  Hanna Leicht; Martin Berwig; Hermann-Josef Gertz
Journal:  J Int Neuropsychol Soc       Date:  2010-03-01       Impact factor: 2.892

5.  Awareness of disease in dementia: factor structure of the assessment scale of psychosocial impact of the diagnosis of dementia.

Authors:  Marcia C N Dourado; Daniel C Mograbi; Raquel L Santos; Maria Fernanda B Sousa; Marcela L Nogueira; Tatiana Belfort; Jesus Landeira-Fernandez; Jerson Laks
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  Anosognosia and Alzheimer's disease: the role of depressive symptoms in mediating impaired insight.

Authors:  C A Smith; V W Henderson; C A McCleary; G A Murdock; J G Buckwalter
Journal:  J Clin Exp Neuropsychol       Date:  2000-08       Impact factor: 2.475

7.  Decreased awareness of cognitive deficits in patients with mild dementia of the Alzheimer type.

Authors:  C Derouesné; S Thibault; S Lagha-Pierucci; V Baudouin-Madec; D Ancri; L Lacomblez
Journal:  Int J Geriatr Psychiatry       Date:  1999-12       Impact factor: 3.485

8.  Insight for impairment in independent living skills in Alzheimer's disease and multi-infarct dementia.

Authors:  B H DeBettignies; R K Mahurin; F J Pirozzolo
Journal:  J Clin Exp Neuropsychol       Date:  1990-03       Impact factor: 2.475

9.  Clinical differences in patients with Alzheimer's disease according to the presence or absence of anosognosia: implications for perceived quality of life.

Authors:  Josep L Conde-Sala; Ramón Reñé-Ramírez; Oriol Turró-Garriga; Jordi Gascón-Bayarri; Montserrat Juncadella-Puig; Laura Moreno-Cordón; Vanesa Viñas-Diez; Josep Garre-Olmo
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 10.  A Systematic Review of Metacognitive Differences Between Alzheimer's Disease and Frontotemporal Dementia.

Authors:  Sarah J DeLozier; Deana Davalos
Journal:  Am J Alzheimers Dis Other Demen       Date:  2015-12-24       Impact factor: 2.035

View more
  5 in total

1.  Anosognosia in Early- and Late-Onset Dementia and Its Association With Neuropsychiatric Symptoms.

Authors:  Manuela Tondelli; Chiara Galli; Giulia Vinceti; Luigi Fiondella; Simone Salemme; Chiara Carbone; Maria Angela Molinari; Annalisa Chiari; Giovanna Zamboni
Journal:  Front Psychiatry       Date:  2021-05-13       Impact factor: 4.157

2.  Associations between Cortical Thickness and Metamemory in Alzheimer's Disease.

Authors:  Tugce Duran; Ellen Woo; Diana Otero; Shannon L Risacher; Eddie Stage; Apoorva B Sanjay; Kwangsik Nho; John D West; Meredith L Phillips; Naira Goukasian; Kristy S Hwang; Liana G Apostolova
Journal:  Brain Imaging Behav       Date:  2022-01-22       Impact factor: 3.224

3.  Altered Interplay Among Large-Scale Brain Functional Networks Modulates Multi-Domain Anosognosia in Early Alzheimer's Disease.

Authors:  Jose Manuel Valera-Bermejo; Matteo De Marco; Annalena Venneri
Journal:  Front Aging Neurosci       Date:  2022-02-03       Impact factor: 5.750

4.  The role of dyadic cognitive report and subjective cognitive decline in early ADRD clinical research and trials: Current knowledge, gaps, and recommendations.

Authors:  Rachel L Nosheny; Rebecca Amariglio; Sietske A M Sikkes; Carol Van Hulle; Maria Aparecida Camargos Bicalho; N Maritza Dowling; Sonia Maria Dozzi Brucki; Zahinoor Ismail; Kensaku Kasuga; Elizabeth Kuhn; Katya Numbers; Anna Aaronson; Davide Vito Moretti; Arturo X Pereiro; Gonzalo Sánchez-Benavides; Allis F Sellek Rodríguez; Prabitha Urwyler; Kristina Zawaly
Journal:  Alzheimers Dement (N Y)       Date:  2022-10-04

Review 5.  Alzheimer's Disease and Empathic Abilities: The Proposed Role of the Cingulate Cortex.

Authors:  Marina Ávila-Villanueva; Jaime Gómez-Ramírez; Jesús Ávila; Miguel A Fernández-Blázquez
Journal:  J Alzheimers Dis Rep       Date:  2021-05-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.